ADG-106 is under clinical development by Adagene Suzhou and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase I drugs for Non-Hodgkin Lymphoma have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ADG-106’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ADG-106 is under development for the treatment of solid tumors, human epidermal growth factor receptor 2 negative breast cancer (HER2- breast cancer), non-Hodgkin lymphoma, hepatocellular carcinoma, non-small cell lung cancer, colon cancer and hematological malignancies. The drug candidate is developed by dynamic precision library platform (DPL). It acts by targeting CD137. It is administered through intravenous route. The drug candidate is being developed based on Neobody technology.
Adagene Suzhou overview
Adagene Suzhou (Adagene) is a biotechnology company which develops immune-oncology antibodies for the treatment of cancer. It is investigating ADG106, an agonist monoclonal antibody (mAb) to treat non-Hodgkin lymphoma and solid tumors. The company utilizes SAFEbody, a proprietary antibody masking technology which is activated only in disease tissues further reducing the spread of disease to the entire body and enhancing the therapeutic window for antibodies; and dynamic precision library (DPL) platform to advance antibody discovery. Adagene was funded by GP Healthcare Capital, Eight Roads Ventures, F-Prime Capital Partners, General Atlantic and other companies. The company has operations in San Francisco, California, the US. Adagene is headquartered in Suzhou, Jiangsu, China.
For a complete picture of ADG-106’s drug-specific PTSR and LoA scores, buy the report here.